Key Points
- Insider sale: VP Daniel Lippis sold 619 Edwards Lifesciences shares for approximately $56,967 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct ownership by 1.52% to 40,034 shares.
- Strong quarterly results: Edwards reported quarterly EPS of $0.78, exceeding estimates by $0.04, while revenue rose 13.6% year over year to $1.74 billion. The company guided for third-quarter 2026 EPS of $0.71–$0.77 and full-year EPS of $2.95–$3.05.
- Positive analyst sentiment: Seventeen analysts rate the stock a Buy and six rate it a Hold, producing a consensus “Moderate Buy” rating and a $100.27 target price. Institutional investors own 79.46% of the company.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 619 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company's stock, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Edwards Lifesciences Stock Up 1.7%
Shares of NYSE:EW opened at $93.59 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The business's 50 day simple moving average is $88.38 and its two-hundred day simple moving average is $84.20. The firm has a market cap of $53.89 billion, a P/E ratio of 53.79, a PEG ratio of 2.31 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the firm earned $0.67 earnings per share. Edwards Lifesciences's revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the first quarter worth about $25,000. JPL Wealth Management LLC purchased a new stake in Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter valued at about $26,000. RMG Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $26,000. Finally, TrinityBridge Ltd bought a new position in shares of Edwards Lifesciences during the 2nd quarter worth approximately $27,000. 79.46% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the stock. Evercore reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Barclays restated an "overweight" rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. JPMorgan Chase & Co. lifted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a "hold" rating in a report on Friday, April 24th. Finally, Wall Street Zen lowered Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $100.27.
Read Our Latest Report on EW
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
